REVELATION BIOSCIENCES INC (REVB) Fundamental Analysis & Valuation

NASDAQ:REVB • US76135L8046

Current stock price

1.19 USD
-0.01 (-0.83%)
At close:
1.24 USD
+0.05 (+4.2%)
After Hours:

This REVB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. REVB Profitability Analysis

1.1 Basic Checks

  • REVB had negative earnings in the past year.
  • In the past year REVB has reported a negative cash flow from operations.
  • In the past 5 years REVB always reported negative net income.
  • In the past 5 years REVB always reported negative operating cash flow.
REVB Yearly Net Income VS EBIT VS OCF VS FCFREVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • REVB's Return On Assets of -109.52% is on the low side compared to the rest of the industry. REVB is outperformed by 78.14% of its industry peers.
  • REVB's Return On Equity of -127.98% is on the low side compared to the rest of the industry. REVB is outperformed by 60.15% of its industry peers.
Industry RankSector Rank
ROA -109.52%
ROE -127.98%
ROIC N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REVB Yearly ROA, ROE, ROICREVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K 8K 10K

1.3 Margins

  • REVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REVB Yearly Profit, Operating, Gross MarginsREVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. REVB Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for REVB has been increased compared to 1 year ago.
  • The number of shares outstanding for REVB has been increased compared to 5 years ago.
  • There is no outstanding debt for REVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
REVB Yearly Shares OutstandingREVB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
REVB Yearly Total Debt VS Total AssetsREVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -4.76, we must say that REVB is in the distress zone and has some risk of bankruptcy.
  • REVB has a worse Altman-Z score (-4.76) than 62.48% of its industry peers.
  • REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.76
ROIC/WACCN/A
WACCN/A
REVB Yearly LT Debt VS Equity VS FCFREVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M -15M

2.3 Liquidity

  • A Current Ratio of 6.92 indicates that REVB has no problem at all paying its short term obligations.
  • REVB has a better Current ratio (6.92) than 68.09% of its industry peers.
  • REVB has a Quick Ratio of 6.92. This indicates that REVB is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.92, REVB is doing good in the industry, outperforming 68.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.92
REVB Yearly Current Assets VS Current LiabilitesREVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. REVB Growth Analysis

3.1 Past

  • REVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.41%, which is quite impressive.
EPS 1Y (TTM)84.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.36% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.52%
EPS Next 2Y39.56%
EPS Next 3Y26.62%
EPS Next 5Y16.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
REVB Yearly Revenue VS EstimatesREVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 50M 100M 150M
REVB Yearly EPS VS EstimatesREVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. REVB Valuation Analysis

4.1 Price/Earnings Ratio

  • REVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REVB Price Earnings VS Forward Price EarningsREVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REVB Per share dataREVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

  • REVB's earnings are expected to grow with 26.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.56%
EPS Next 3Y26.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. REVB Dividend Analysis

5.1 Amount

  • REVB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REVB Fundamentals: All Metrics, Ratios and Statistics

REVELATION BIOSCIENCES INC

NASDAQ:REVB (3/20/2026, 8:20:24 PM)

After market: 1.24 +0.05 (+4.2%)

1.19

-0.01 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners8.27%
Inst Owner Change-99.88%
Ins Owners2.13%
Ins Owner Change48.71%
Market Cap4.43M
Revenue(TTM)N/A
Net Income(TTM)-14.08M
Analysts82.86
Price Target86.7 (7185.71%)
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.13%
Min EPS beat(2)-54.27%
Max EPS beat(2)-29.98%
EPS beat(4)2
Avg EPS beat(4)-1.02%
Min EPS beat(4)-54.27%
Max EPS beat(4)69.93%
EPS beat(8)5
Avg EPS beat(8)-1.97%
EPS beat(12)8
Avg EPS beat(12)42.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-65.4
EYN/A
EPS(NY)-4.24
Fwd EYN/A
FCF(TTM)-2.7
FCFYN/A
OCF(TTM)-2.7
OCFYN/A
SpS0
BVpS2.96
TBVpS2.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -109.52%
ROE -127.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.92
Altman-Z -4.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.31%
EPS Next Y93.52%
EPS Next 2Y39.56%
EPS Next 3Y26.62%
EPS Next 5Y16.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.3%
OCF growth 3YN/A
OCF growth 5YN/A

REVELATION BIOSCIENCES INC / REVB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REVELATION BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to REVB.


What is the valuation status for REVB stock?

ChartMill assigns a valuation rating of 1 / 10 to REVELATION BIOSCIENCES INC (REVB). This can be considered as Overvalued.


What is the profitability of REVB stock?

REVELATION BIOSCIENCES INC (REVB) has a profitability rating of 0 / 10.


What is the financial health of REVELATION BIOSCIENCES INC (REVB) stock?

The financial health rating of REVELATION BIOSCIENCES INC (REVB) is 6 / 10.